Erratum: Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging

Correction to: Gene Therapy (2012) 19, 532–542; doi:10.1038/gt.2011.131

Since the publication of this paper, the author has noticed that several references were numbered incorrectly.

The Reference 62 found on page 539 should be reference 26.

The Correct references are now shown below:

References 1 to 16 are correct.

17 Ibrahimi A, Vande Velde G, Reumers V, Toelen J, Thiry I, Vandeputte C et al. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther 2009; 20: 845–860.

18 Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 589–594.

19 Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010; 78: 142–147.

20 Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol 2006; 23: 99–108.

21 Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972; 48: 1565–1571.

22 Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 1992; 10: 265–269.

23 Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res 1998; 18: 3399–3406.

24 Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther 2007; 7: 975–995.

25 Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther 2007; 15: 1129–1136.

26 Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, Margison GP et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J 2006; 3: 14.

27 Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006; 12: 4306–4314.

28 Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008; 16:1382–1391.

References 29 to 63 are correct.

The correct reference 64 is now shown below:

64 Fraefel C. Gene delivery using helper virus-free HSV-1 amplicon vectors. Curr Protoc Neurosci 2007; Chapter 4: Unit 4.14.